Meridian Wealth Partners’s Centessa Pharmaceuticals CNTA Stock Holding History

Meridian Wealth Partners’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18,101	Closed	-$719K	–	128
2026 Q1	$719K	Hold	18,101	–	–	0.1%	50
2025 Q4	$453K	Hold	18,101	–	–	0.06%	67
2025 Q3	$439K	Sell	18,101 -20,000	-52%	-$355K	0.06%	69
2025 Q2	$501K	Buy	+38,101	New	+$483K	0.07%	61

Meridian Wealth Partners's CNTA Position: Q2 2026 in Review

Meridian Wealth Partners sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 18,101 shares — an estimated $719K sold.

Meridian Wealth Partners first reported a position in CNTA in Q2 2025 and held it in 4 quarters. The position peaked at $719K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Meridian Wealth Partners reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Meridian Wealth Partners sold 18,101 Centessa Pharmaceuticals shares in Q2 2026, an estimated $719K.
Meridian Wealth Partners first reported a position in Centessa Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Meridian Wealth Partners's Centessa Pharmaceuticals position peaked at $719K in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Meridian Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.